Trial reportBritish journal of cancer2012
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.
Trial report in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00886028 ("Phase II Study), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma "
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma.Thoracic cancer · 2021Trial
- Druggable upregulated proteins in EWS-FLI-driven Ewing sarcoma as emerging new therapeutic targets.American journal of translational research · 2025Review
- Article
- Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies.International journal of nanomedicine · 2024Article
- Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.Frontiers in chemistry · 2023Review
- Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review.Current issues in molecular biology · 2022Review
- Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System.Current drug metabolism · 2022Review
- Programmed cell death, redox imbalance, and cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2021Review
- Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2020Review
- Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects.European journal of hospital pharmacy : science and practice · 2020Review
- Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.Advanced drug delivery reviews · 2019Review
- Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).Thoracic cancer · 2019Article
- The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.Translational lung cancer research · 2018Article
- Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Rethinking cancer nanotheranostics.Nature reviews. Materials · 2017Article
- Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.Journal of thoracic disease · 2016Article
- Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy.Theranostics · 2016Article
- Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.Annals of surgical oncology · 2015Article
- Update on current and potential nanoparticle cancer therapies.Current opinion in oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy based on platinum is the standard treatment for unresectable malignant pleural mesothelioma (MPM). Liposomal doxorubicin (LD) consists of pegylated phospholipid vesicles that encapsulate doxorubicin-enhancing liposome deposition in the tumour. We evaluated the toxicity profile and anti-tumour activity of cisplatin plus LD in untreated patients with MPM, as well as (99m)Tc-LD distribution in MPM lesions after chemotherapy administration.
methodsA total of 38 patients with non-resectable MPM received LD 40 mg m(-2) and cisplatin 60 mg m(-2) every 21 days. Gamma camera images of (99m)Tc-LD were acquired to evaluate LD accumulation in measurable tumour tissue. The study was registered in Clinical Trials (NCT00886028).
resultsIn all, 72% of patients were stage III and 28% were stage IV. Eighty four percent and 16% have high and low risk acording EORTC respectively. The median time to progression was 4.6 months (95% confidence interval (95% CI: 3.4-5.9 months), and median overall survival (OS) was 19.6 months (15.2-37.2 months). Patients that responded to chemotherapy treatment had better survival than patients who did not. Functional physical scales, dysnea, cough, and chest/arm pain demonstrated improvement. The accumulation ratio of LD in tumour and soft tissues vs liver was 0.78±0.16 and 0.29±0.09, respectively. After 1 h of administration, LD uptake in tumour tissue was higher than in soft tissue (P< 0.001).
conclusionThe combination of LD and cisplatin results in an active therapeutic regimen for unresectable MPM, with an acceptable toxicity profile and improvement in quality of life. (99m)Tc-LD showed higher levels of tumour uptake as compared with surrounding tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.